Peter Pecháň

1.5k total citations
36 papers, 1.3k citations indexed

About

Peter Pecháň is a scholar working on Molecular Biology, Genetics and Epidemiology. According to data from OpenAlex, Peter Pecháň has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 23 papers in Genetics and 10 papers in Epidemiology. Recurrent topics in Peter Pecháň's work include Virus-based gene therapy research (18 papers), Herpesvirus Infections and Treatments (10 papers) and RNA Interference and Gene Delivery (8 papers). Peter Pecháň is often cited by papers focused on Virus-based gene therapy research (18 papers), Herpesvirus Infections and Treatments (10 papers) and RNA Interference and Gene Delivery (8 papers). Peter Pecháň collaborates with scholars based in United States, Germany and Switzerland. Peter Pecháň's co-authors include Xandra O. Breakefield, Ulrich Herrlinger, Miguel Sena‐Esteves, Faith H. Barnett, W. Seifert, Nikolai G. Rainov, Alice K. Jacobs, Maureen Chase, Kamal Chowdhury and E. Antonio Chiocca and has published in prestigious journals such as Journal of Virology, The FASEB Journal and Cellular and Molecular Life Sciences.

In The Last Decade

Peter Pecháň

35 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Pecháň United States 20 786 781 316 189 130 36 1.3k
Oumeya Adjali France 18 759 1.0× 581 0.7× 90 0.3× 192 1.0× 72 0.6× 53 1.1k
Waixing Tang United States 20 1.6k 2.0× 573 0.7× 509 1.6× 136 0.7× 342 2.6× 26 2.5k
Kye Chesnut United States 14 1.2k 1.5× 1.3k 1.6× 255 0.8× 256 1.4× 20 0.2× 16 2.0k
Peter Colosi United States 28 2.6k 3.3× 2.1k 2.7× 259 0.8× 455 2.4× 337 2.6× 46 3.5k
Tony N. Jelsma Canada 8 487 0.6× 468 0.6× 52 0.2× 238 1.3× 56 0.4× 10 760
Véronique Blouin France 22 1.0k 1.3× 993 1.3× 109 0.3× 190 1.0× 33 0.3× 37 1.3k
Guang Qu United States 12 892 1.1× 849 1.1× 122 0.4× 198 1.0× 81 0.6× 18 1.1k
David M. Markusic United States 26 1.5k 1.9× 1.4k 1.8× 236 0.7× 641 3.4× 26 0.2× 54 2.4k
Vasiliki Kalatzis France 27 1.3k 1.6× 390 0.5× 71 0.2× 74 0.4× 197 1.5× 69 2.6k
Ché Serguera France 16 630 0.8× 427 0.5× 76 0.2× 78 0.4× 11 0.1× 29 1.1k

Countries citing papers authored by Peter Pecháň

Since Specialization
Citations

This map shows the geographic impact of Peter Pecháň's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Pecháň with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Pecháň more than expected).

Fields of papers citing papers by Peter Pecháň

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Pecháň. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Pecháň. The network helps show where Peter Pecháň may publish in the future.

Co-authorship network of co-authors of Peter Pecháň

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Pecháň. A scholar is included among the top collaborators of Peter Pecháň based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Pecháň. Peter Pecháň is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shen, Feng, Li Mao, Weihong Zhu, et al.. (2015). Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1. Gene Therapy. 22(11). 893–900. 5 indexed citations
2.
Pecháň, Peter, et al.. (2014). Aurintricarboxylic acid increases yield of HSV-1 vectors. Molecular Therapy — Methods & Clinical Development. 1. 6–6. 4 indexed citations
3.
Bagley, Rebecca G., Leslie Kurtzberg, William Weber, et al.. (2011). sFLT01: A Novel Fusion Protein with Antiangiogenic Activity. Molecular Cancer Therapeutics. 10(3). 404–415. 20 indexed citations
4.
Tuo, Jingsheng, Jijing Pang, Xiaoguang Cao, et al.. (2011). AAV5-mediated sFLT01 gene therapy arrests retinal lesions in Ccl2−/−/Cx3cr1−/− mice. Neurobiology of Aging. 33(2). 433.e1–433.e10. 19 indexed citations
5.
Tuo, Jingsheng, Jijing Pang, Xiaoguang Cao, et al.. (2010). AAV‐mediated sFLT‐1 gene therapy ameliorates retinal lesions in Ccl2/Cx3cr1 deficient mice. The FASEB Journal. 24(S1). 4509–4509. 1 indexed citations
6.
Pecháň, Peter, Hillard Rubin, Michael Lukason, et al.. (2008). Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Therapy. 16(1). 10–16. 83 indexed citations
7.
Ye, Guo-jie, Chris Drogemuller, Darby L. Thomas, et al.. (2006). 503. A Novel Herpes Simplex Virus Helper Based Production of Adeno- Associated Virus Vectors for Treatment of Retinal Angiogenesis. Molecular Therapy. 13. S194–S194. 2 indexed citations
8.
Rainov, Nikolai G., Keiro Ikeda, Ulrich Herrlinger, et al.. (1999). Intraarterial Delivery of Adenovirus Vectors and Liposome-DNA Complexes to Experimental Brain Neoplasms. Human Gene Therapy. 10(2). 311–318. 43 indexed citations
9.
Pecháň, Peter, Ulrich Herrlinger, Manish K. Aghi, Alice K. Jacobs, & Xandra O. Breakefield. (1999). Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. The Journal of Gene Medicine. 1(3). 176–185. 12 indexed citations
10.
Jacoby, David, Peter Pecháň, Cornel Fraefel, et al.. (1997). HSV/AAV Hybrid Amplicon Vectors Extend Transgene Expression in Human Glioma Cells. Human Gene Therapy. 8(3). 359–370. 108 indexed citations
11.
Chase, Maureen, Ulrich Herrlinger, Alice K. Jacobs, et al.. (1997). Therapeutic Efficiency and Safety of a Second-Generation Replication-Conditional HSV1 Vector for Brain Tumor Gene Therapy. Human Gene Therapy. 8(17). 2057–2068. 145 indexed citations
12.
Lin, Qing, Lee Anna Cunningham, Leon G. Epstein, et al.. (1997). Human Fetal Astrocytes as an Ex Vivo Gene Therapy Vehicle for Delivering Biologically Active Nerve Growth Factor. Human Gene Therapy. 8(3). 331–339. 22 indexed citations
13.
Kramm, Christof M., Nikolai G. Rainov, Miguel Sena‐Esteves, et al.. (1996). Long-Term Survival in a Rodent Model of Disseminated Brain Tumors by Combined Intrathecal Delivery of Herpes Vectors and Ganciclovir Treatment. Human Gene Therapy. 7(16). 1989–1994. 53 indexed citations
14.
Pecháň, Peter, Richard Thompson, Robert R. Dunn, et al.. (1996). A Novel ‘Piggyback’ Packaging System for Herpes Simplex Virus Amplicon Vectors. Human Gene Therapy. 7(16). 2003–2013. 28 indexed citations
15.
Kramm, Christof M, Miguel Sena‐Esteves, Faith H. Barnett, et al.. (1995). Gene Therapy for Brain Tumors. Brain Pathology. 5(4). 345–381. 88 indexed citations
16.
Pecháň, Peter, Kamal Chowdhury, & W. Seifert. (1992). Free radicals induce gene expression of NGF and bFGF in rat astrocyte culture. Neuroreport. 3(6). 469–472. 68 indexed citations
17.
Wachtel, Stephen S., et al.. (1991). Bkm satellite DNA and ZFY in the coral reef fish Anthias squamipinnis. Genome. 34(4). 612–617. 14 indexed citations
18.
Pecháň, Peter, et al.. (1989). Stability of the recombinant plasmids carrying the α-amylase gene inBacillus strains. Biotechnology Letters. 11(10). 723–728. 3 indexed citations
19.
Pecháň, Peter. (1985). Murine antibody induced-sex-ratio changes in Drosophila melanogaster. Journal of Heredity. 76(3). 220–220. 4 indexed citations
20.
Pecháň, Peter, et al.. (1980). H-Y Evolution. Cellular and Molecular Life Sciences. 36(3). 356–357. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oumeya Adjali Breakdown of academic impact, for papers by Waixing Tang Breakdown of academic impact, for papers by Kye Chesnut Breakdown of academic impact, for papers by Peter Colosi Breakdown of academic impact, for papers by Tony N. Jelsma Breakdown of academic impact, for papers by Véronique Blouin Breakdown of academic impact, for papers by Guang Qu Breakdown of academic impact, for papers by David M. Markusic Breakdown of academic impact, for papers by Vasiliki Kalatzis Breakdown of academic impact, for papers by Ché Serguera
Rankless by CCL
2026